Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment
regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected
patients.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
HIV Protease Inhibitors Protease Inhibitors Ritonavir Tipranavir